Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
— Meeting to Reconvene on
The record date for the EGM continues to be the close of business on
- Vote by Internet at www.proxyvote.com until
11:59 p.m. ,U.S. Eastern Time, onJanuary 17, 2022 using the pin number/other unique identifier appearing on the proxy card.
- Vote by telephone by calling the toll-free telephone number 1-800-690-6903 until
11:59 p.m. ,U.S. Eastern Time, onJanuary 17, 2022 using the pin number/other unique identifier appearing on the proxy card.
- Vote by mail by completing, dating and signing the proxy card, and returning it in the postage-paid envelope provided with the Proxy Statement.
- Vote in person by attending the EGM.
To vote shares held in “street name,” holders will need to follow the directions provided by their brokerage firms.
Proxies previously submitted in respect of the EGM will be voted at the reconvened EGM unless properly revoked; shareholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. No changes have been made to the proposal to be voted on by shareholders at the EGM. The Proxy Statement is available at https://www.sec.gov/ and at www.proxyvote.com.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for
CONTACTS:
For Investors
Nabriva Therapeutics plc
IR@Nabriva.com
For Media
Ogilvy
andrea.greif@ogilvy.com
914-772-3027

Source: Nabriva Therapeutics US, Inc